Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haidan Guo

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Journal for Immunotherapy of Cancer|March 8, 2019
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Journal for Immunotherapy of Cancer|February 13, 2019
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Nature|July 22, 2021
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Nature|October 5, 2021
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Journal for Immunotherapy of Cancer|March 8, 2019
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Journal for Immunotherapy of Cancer|February 13, 2019
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Nature|July 22, 2021
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Nature|October 5, 2021
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Pageof 4